2616.HK

The Latest: Drug maker CStone Pharmaceuticals (2616.HK) announced on Tuesday its Pralsetinib, also known by the brand name Gavreto, was approved by China’s drug regulator as a first-line treatment for advanced non-small cell lung cancer.

Looking Up: The move represents the third approved application by China’s National Medical Products Administration (NMPA) for the anti-cancer drug, which is part of a class known as targeted RET inhibitors.

Take Note: Pralsetinib is facing competition from other similar drugs. One such drug, Selpercatinib, developed by rival Innovent Biologics (1801.HK), was approved for sale in China last October.

Digging Deeper: CStone is among a new generation of young Chinese companies that are bringing cutting-edge new drugs, both self-developed and licensed, to the global and China markets. Nearly all of the companies are losing money as they build up their drug portfolios, but many are also starting to record significant revenue as more of their drugs get approved. CStone is one of the more advanced companies, reporting 481 million yuan ($67 million) in revenue last year and a 903 million yuan loss.

Market Reaction: CStone shares jumped 6.2% in Hong Kong on Tuesday after the announcement to close at HK$2.59. The stock trades near the lower end of its 52-week range.

Have a great investment idea but don’t know how to spread the word? We can help! Contact us for more details.

To subscribe to Bamboo Works weekly free newsletter, click here

Reporting by Doug Young

Recent Articles

INDUSTRY BRIEF: Changan-Dongfeng merger crashes

A long-rumored merger between Changan Automobile and Dongfeng Motor has officially collapsed after nearly four months of speculation. Changan Automobile Co. Ltd. (000625.SZ) announced on Thursday that its parent, China…
Qudian abandons last mile delivery

Qudian: A slow-motion privatization?

The company said it is contemplating winding down its last-mile delivery service after stiff competition caused its revenue to plunge in the first quarter Key Takeaways: Qudian’s revenue fell by…

BRIEF: Greentown sales rise in May

Property developer Greentown China Holdings Ltd. (3900.HK) on Thursday reported its sales totaled 18.6 billion yuan ($2.59 billion) in May, up 14% year-over-year and up by an even stronger 60%…
Yeahka secures bridgehead in U.S. payments market

Yeahka secures bridgehead in U.S. payments market

The Chinese fintech has cleared one of many regulatory hurdles to enter the U.S. digital payments business after gaining a state-level operating license Key Takeaways: After getting U.S. federal clearance,…